The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | The value of CTCs and cfDNA as novel biomarkers in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the value of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) as novel biomarkers in multiple myeloma (MM). Dr Paiva highlights that CTCs and cfDNA present potential minimally invasive methods for monitoring the risk of progression in patients with precursor conditions and for the regular assessment of measurable residual disease (MRD) status in patients in remission. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that both CTCs and ctDNA have clear value for the staging of patients with myeloma. In fact, for the staging at different stages. The reason I say this is because there is more and more interest for accurate predictions of patients with precursor conditions at risk of developing active disease. This can only be achieved by longitudinal frequent testing and longitudinal frequent testing requires the ability for testing using minimally invasive methods in samples other than the bone marrow aspirate and therefore the interest for CTCs and ctDNA in those patients with precursor conditions...
I think that both CTCs and ctDNA have clear value for the staging of patients with myeloma. In fact, for the staging at different stages. The reason I say this is because there is more and more interest for accurate predictions of patients with precursor conditions at risk of developing active disease. This can only be achieved by longitudinal frequent testing and longitudinal frequent testing requires the ability for testing using minimally invasive methods in samples other than the bone marrow aspirate and therefore the interest for CTCs and ctDNA in those patients with precursor conditions. And then the MRD setting, patients fortunately are living longer and longer, some of whom even with treatment-free intervals, and therefore there will be more and more interest to know what is the remission status of the patient down to the MRD level. And we cannot work in a scenario in which patients will have bone marrow aspirates every six or 12 months for years and years until a potential disease progression. Again, this requires high sensitive methods for minimally invasive assessment of MRD and there again I think there is promising data showing the value of CTCs as well as ctDNA.
Read more...
